Sign in Subscribe
Vaccines

Johnson & Johnson's One-Dose COVID-19 Vaccine Ready to Shake Up Immunization Push

Strategic Insights

— 1 min read

Johnson & Johnson's one-dose COVID-19 vaccine regimen is poised to play a crucial role in expanding vaccine access in the US and beyond, despite the faltering immunization push. The pharmaceutical giant is in the final stages of data analysis for its phase 3 trial, with CEO Alex Gorsky stating that the company hopes to have the information "very soon." J&J's adenovirus-based vaccine candidate is on track to deliver its first efficacy numbers, which could be a game-changer in the fight against COVID-19.

Key Takeaways:

  • Johnson & Johnson's one-dose COVID-19 vaccine is in the final stages of data analysis for its phase 3 trial.
  • The company hopes to have the information "very soon," according to CEO Alex Gorsky.
  • J&J's adenovirus-based vaccine candidate is on track to deliver its first efficacy numbers, which could be a game-changer in the fight against COVID-19.
  • The Pfizer-BioNTech and Moderna vaccines posted efficacy numbers better than 90%, while AstraZeneca's vaccine was 70% effective on average.
  • J&J's vaccine works with just one dose, which Operation Warp Speed official Moncef Slaoui said could be a "game-changer."
  • The company is also testing its shot as a two-dose regimen.
  • Johnson & Johnson's production is on track to deliver hundreds of millions of doses in the first half of 2021, and nearly 1 billion doses in 2021.
  • Novavax plans to report interim phase 3 data in the first quarter and is already stockpiling doses in the event the program wins regulatory green lights.
  • Novavax has established a worldwide manufacturing network that will be able to produce 2 billion vaccine doses per year.

Statistics:

  • As of Monday, about 7 million vaccine doses were administered in the US.
  • Johnson & Johnson intends to produce nearly 1 billion doses in 2021.
  • Novavax plans to produce 2 billion vaccine doses per year.
  • The Pfizer-BioNTech and Moderna vaccines posted efficacy numbers better than 90%.
  • AstraZeneca's vaccine was 70% effective on average, but a half-dose regimen was 90% effective.

Sources:

  • (https://www.fiercepharma.com/pharma/covid-19-shots-from-astrazeneca-and-j-j-must-succeed-to-meet-us-vaccination-goal-slaoui)
  • (https://nypost.com/2020/12/30/one-shot-covid-vaccine-likely-in-february-warp-speed-leader/)
  • (https://www.fiercepharma.com/pharma/jpm-day-1-bms-oncology-ambitions-novavax-and-regeneron-2021-plans-and-next-round-covid-19)

Read more